Evidence boundary
There is no reliable contemporary sermorelin headache rate
Sermorelin is a growth hormone-releasing hormone analog that stimulates pituitary growth-hormone signaling. A 2026 review of therapeutic peptides lists flushing and injection-site discomfort among sermorelin effects, but it does not provide a controlled headache incidence rate for current compounded products. Older sermorelin literature is limited, legacy Geref products are discontinued, and formulations dispensed today may differ by pharmacy, concentration, excipients, route, storage, and handling. A headache that follows treatment therefore deserves assessment without being automatically dismissed as expected or automatically attributed to the peptide.
- Do not turn a forum count, clinic FAQ, spontaneous report, or broad GH-axis review into a percentage that predicts an individual patient’s risk.
- The timing of a symptom can support clinical review, but timing alone does not prove causation or rule out migraine, infection, blood-pressure problems, medication effects, dehydration, or another diagnosis.
- Ask the prescriber what evidence supports the proposed product, what adverse events have been seen in that practice, and how symptoms are documented and reported.